Raymond James downgrades loanDepot (NYSE:LDI) from Outperform to Market Perform.
Belite Bio Priced 6M ADS IPO @$6/ADS
Belite Bio, Inc (NASDAQ: BLTE) ("Belite" or the "Company"), a clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases such as dry AMD and Stargardt disease, and metabolic diseases, today announced the pricing of its initial public offering of 6 million American Depositary Shares (
